Drug Profile
Research programme: eye disorders therapy - IOMED/Santen
Alternative Names: Eye disorders therapy research programme - IOMED/SantenLatest Information Update: 15 Feb 2002
Price :
$50
*
At a glance
- Originator IOMED
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Eye disorders
Most Recent Events
- 15 Feb 2002 Discontinued-Preclinical for Eye disorders in USA (Intraocular)
- 20 Jul 2001 Preclinical development for Eye disorders in USA (Intraocular)